Anlon Healthcare FY26 Income Surges 43%, Eyes Strong Growth

Anlon Healthcare's total income for FY26 reached ₹172.22 crore, marking a significant 42.98% year-on-year increase from ₹120.46 crore in FY25. The company's Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) also saw a strong jump of 47.55% to ₹47.77 crore.

Reader Takeaway: Strong annual growth driven by expansion plans, but quarterly margins face short-term pressure from rising costs.

What just happened

Anlon Healthcare Ltd announced its financial results for the fiscal year ending March 31, 2026 (FY26). The company reported consolidated total income of ₹172.22 crore, a substantial increase of 42.98% compared to FY25. EBITDA also grew by 47.55% to ₹47.77 crore. For the fourth quarter (Q4 FY26), total income stood at ₹50.90 crore, up from ₹48.97 crore in Q4 FY25. However, Profit Before Tax (PBT) and Profit After Tax (PAT) declined in Q4 FY26 to ₹14.44 crore and ₹11.07 crore, respectively, from ₹15.49 crore and ₹16.65 crore in the prior-year period.

Why this matters

The strong annual performance indicates healthy business growth, driven by strategic initiatives. The planned capacity expansion and acquisitions are aimed at strengthening the company's market position and backward integration. However, the quarterly profit dip signals potential headwinds from rising operational costs and raw material prices, which could impact profitability if not managed effectively.

The backstory

Anlon Healthcare has been focusing on scaling its operations. The company recently completed the acquisition of Apiqo Organics and Bizotic Life Science, aiming to enhance its manufacturing capabilities and backward integration. This growth phase involves significant capital expenditure and operational scaling.

What changes now

The company has outlined ambitious revenue targets for FY27 (₹380-400 crore) and FY28 (₹700-800 crore), with a target EBITDA margin range of 25-30%. Management is confident about becoming cash flow positive by the end of FY27. A key development is the planned Capex of ₹130 crore for a new facility, expected to be commissioned by Q1 FY28. Funding for this will be a mix of debt and internal accruals.

Risks to watch

Investors should monitor the company's working capital, as receivable days currently range between 130-140 days, which can strain liquidity. Volatility in raw material prices (solvents, catalysts) is also a concern, potentially affecting margins. Additionally, the company is working to resolve a historical "issuer not cooperating" status with credit rating agencies, which could impact its market perception and cost of borrowing.

Peer comparison

(Information not available in the provided filing. A grounded search would be needed for comparable data on companies like Aarti Industries, Vinati Organics, or other specialty chemical/pharma ingredient manufacturers.)

Context metrics (time-bound)

• FY26 Total Income: ₹172.22 crore (up 42.98% YoY)
• FY26 EBITDA: ₹47.77 crore (up 47.55% YoY)
• Q4 FY26 PAT: ₹11.07 crore (down from ₹16.65 crore YoY)
• Planned Capex: ₹130 crore (commissioning by Q1 FY28)
• FY27 Revenue Target: ₹380-400 crore

What to track next

Investors should track the implementation of the new payment recovery policy to improve receivable days, the company's ability to pass on increased raw material costs, progress on the new capacity expansion, and the achievement of its revenue and EBITDA margin targets. Resolution of the 'issuer not cooperating' credit rating status is also a key point.